189 related articles for article (PubMed ID: 31521537)
1. PD-L1 Acts as a Promising Immune Marker to Predict the Response to Neoadjuvant Chemotherapy in Breast Cancer Patients.
Du Q; Che J; Jiang X; Li L; Luo X; Li Q
Clin Breast Cancer; 2020 Feb; 20(1):e99-e111. PubMed ID: 31521537
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Immune Reaction and PD-L1 Expression Using Multiplex Immunohistochemistry in HER2-Positive Breast Cancer: The Association With Response to Anti-HER2 Neoadjuvant Therapy.
Hou Y; Nitta H; Wei L; Banks PM; Parwani AV; Li Z
Clin Breast Cancer; 2018 Apr; 18(2):e237-e244. PubMed ID: 29198959
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathologic Factors Associated With Response to Neoadjuvant Anti-HER2-Directed Chemotherapy in HER2-Positive Breast Cancer.
Meisel JL; Zhao J; Suo A; Zhang C; Wei Z; Taylor C; Aneja R; Krishnamurti U; Li Z; Nahta R; O'Regan R; Li X
Clin Breast Cancer; 2020 Feb; 20(1):19-24. PubMed ID: 31806448
[TBL] [Abstract][Full Text] [Related]
4. The immune profile of small HER2-positive breast cancers: a secondary analysis from the APT trial.
Barroso-Sousa R; Barry WT; Guo H; Dillon D; Tan YB; Fuhrman K; Osmani W; Getz A; Baltay M; Dang C; Yardley D; Moy B; Marcom PK; Mittendorf EA; Krop IE; Winer EP; Tolaney SM
Ann Oncol; 2019 Apr; 30(4):575-581. PubMed ID: 30753274
[TBL] [Abstract][Full Text] [Related]
5. PD-L1 expression of the residual tumor serves as a prognostic marker in local advanced breast cancer after neoadjuvant chemotherapy.
Chen S; Wang RX; Liu Y; Yang WT; Shao ZM
Int J Cancer; 2017 Mar; 140(6):1384-1395. PubMed ID: 27925176
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological values of PD-L1 expression in HER2-positive breast cancer.
Kurozumi S; Inoue K; Matsumoto H; Fujii T; Horiguchi J; Oyama T; Kurosumi M; Shirabe K
Sci Rep; 2019 Nov; 9(1):16662. PubMed ID: 31723167
[TBL] [Abstract][Full Text] [Related]
7. Tumour-infiltrating lymphocytes as a prognostic and tamoxifen predictive marker in premenopausal breast cancer: data from a randomised trial with long-term follow-up.
Lundgren C; Bendahl PO; Ekholm M; Fernö M; Forsare C; Krüger U; Nordenskjöld B; Stål O; Rydén L
Breast Cancer Res; 2020 Dec; 22(1):140. PubMed ID: 33357231
[TBL] [Abstract][Full Text] [Related]
8. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
[TBL] [Abstract][Full Text] [Related]
9. The role of programmed death ligand-1 and tumor-infiltrating lymphocytes in breast cancer overexpressing HER2 gene.
Li Y; Opyrchal M; Yao S; Peng X; Yan L; Jabbour H; Khoury T
Breast Cancer Res Treat; 2018 Jul; 170(2):293-302. PubMed ID: 29524062
[TBL] [Abstract][Full Text] [Related]
10. Emerging immune gene signatures as prognostic or predictive biomarkers in breast cancer.
Kwon MJ
Arch Pharm Res; 2019 Nov; 42(11):947-961. PubMed ID: 31707598
[TBL] [Abstract][Full Text] [Related]
11. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
[TBL] [Abstract][Full Text] [Related]
12. Implication of programmed cell death ligand 1 expression in tumor recurrence and prognosis in rectal cancer with neoadjuvant chemoradiotherapy.
Saigusa S; Toiyama Y; Tanaka K; Inoue Y; Mori K; Ide S; Imaoka H; Kawamura M; Mohri Y; Kusunoki M
Int J Clin Oncol; 2016 Oct; 21(5):946-952. PubMed ID: 26919982
[TBL] [Abstract][Full Text] [Related]
13. Infiltrating stromal immune cells in inflammatory breast cancer are associated with an improved outcome and increased PD-L1 expression.
Van Berckelaer C; Rypens C; van Dam P; Pouillon L; Parizel M; Schats KA; Kockx M; Tjalma WAA; Vermeulen P; van Laere S; Bertucci F; Colpaert C; Dirix L
Breast Cancer Res; 2019 Feb; 21(1):28. PubMed ID: 30777104
[TBL] [Abstract][Full Text] [Related]
14. PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients.
Tsang JY; Au WL; Lo KY; Ni YB; Hlaing T; Hu J; Chan SK; Chan KF; Cheung SY; Tse GM
Breast Cancer Res Treat; 2017 Feb; 162(1):19-30. PubMed ID: 28058578
[TBL] [Abstract][Full Text] [Related]
15. The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis.
Yang WF; Wong MCM; Thomson PJ; Li KY; Su YX
Oral Oncol; 2018 Nov; 86():81-90. PubMed ID: 30409325
[TBL] [Abstract][Full Text] [Related]
16. Predictive value of MLH1 and PD-L1 expression for prognosis and response to preoperative chemotherapy in gastric cancer.
Hashimoto T; Kurokawa Y; Takahashi T; Miyazaki Y; Tanaka K; Makino T; Yamasaki M; Nakajima K; Ikeda JI; Mori M; Doki Y
Gastric Cancer; 2019 Jul; 22(4):785-792. PubMed ID: 30617648
[TBL] [Abstract][Full Text] [Related]
17. Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance.
Pelekanou V; Carvajal-Hausdorf DE; Altan M; Wasserman B; Carvajal-Hausdorf C; Wimberly H; Brown J; Lannin D; Pusztai L; Rimm DL
Breast Cancer Res; 2017 Aug; 19(1):91. PubMed ID: 28784153
[TBL] [Abstract][Full Text] [Related]
18. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
19. The predictive and prognostic value of Foxp3+/CD25+ regulatory T cells and PD-L1 expression in triple negative breast cancer.
Zhang L; Wang XI; Ding J; Sun Q; Zhang S
Ann Diagn Pathol; 2019 Jun; 40():143-151. PubMed ID: 31096176
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
